RiverVest Venture Partners related stories
All articles and analysis
RiverVest Venture Partners raises $56mView the latest capital raises
- Securus Medical Group nets $10 mln Series C
Cleveland-based medical device company Securus Medical Group Inc has raised $10 million in Series C financing. Boston Scientific Corp led the round with participation from RiverVest Venture Partners, 3X5 Special Opportunity Fund, University of Michigan and the Global Cardiovascular Innovation Center.
- Tioma nabs $86 mln Series A
St. Louis, Missouri and Brisbane, California-based Tioma Therapeutics Inc, which develops anti-CD47 antibodies that treat solid and hematologic cancers, has secured $86 million in Series A financing. RiverVest Venture Partners, Novo Ventures, Roche Venture Fund and GlaxoSmithKline's corporate venture capital arm S.R. One Limited led the round. In addition to the financing, Dr. John McKearn of RiverVest Venture Partners, Dr. Peter Moldt of Novo Ventures, Carole Nuechterlein of Roche Venture Fund and Jill Carroll of S.R. One have been appointed to Tioma's board of directors, with McKearn serving as chair.
- Amplyx racks up $40.5 mln in RiverVest-led Series B round
San Diego-based Amplyx Pharmaceuticals, which is developing antifungal agents that treat life-threatening fungal infections, has raised $40.5 million in Series B funding. RiverVest Venture Partners led the round with participation from other investors that included New Enterprise Associates and BioMed Ventures. In conjunction with the funding, Dr. Niall O'Donnell, managing director at RiverVest Venture Partners and Ed Mathers, a partner at New Enterprise Associates, were added to Amplyx's board of directors.
Fund Briefs May 18, 2015A recap of recent venture-related fundraisings and filings; plus tables and data on closings worldwide
- RiverVest Venture Partners closes third fund at $80.2 mln
RiverVest Venture Partners has raised $80.2 million for its third fund. RiverVest Venture Fund III LP will focus on pharmaceuticals and therapeutic medical devices with no geographic boundaries.
Fund briefs May 1, 2015A summary of VC fundraisings and filings; plus tables on recent closings worldwide
- RiverVest raises $75.8 mln toward a third fund
RiverVest Venture Partners has raised $75.8 million toward a $150 million third fund, according to a filing with the SEC. The filing says 41 LPs are involved and that the firm hopes to raise another $74.2 million.
- RiverVest, Sante, Third Point Ventures lead funding in Lyric Pharmaceuticals
RiverVest Venture Partners, Sante Ventures and Third Point Ventures have co-led an initial close of a $20.4 million Series A funding round in Lyric Pharmaceuticals Inc, a clinical stage company developing therapeutics for gastrointestinal disease. Lyric closed an $825,000 seed funding round led by RiverVest last year.
- Allakos secures $10 mln
Biotechnology company Allakos has secured an additional $10 million investment from current investors to fund the development of an additional therapeutic antibody. All of the company's current investors participated including Novo Ventures, Alta Partners, RiverVest Venture Partners and the Roche Venture Fund.